News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,055 Results
Type
Article (14026)
Company Profile (283)
Press Release (248746)
Section
Business (79421)
Career Advice (152)
Deals (13208)
Drug Delivery (34)
Drug Development (50363)
Employer Resources (31)
FDA (5694)
Job Trends (5120)
News (144228)
Policy (10019)
Tag
Academia (901)
Alliances (21588)
Alzheimer's disease (780)
Antibody-drug conjugate (ADC) (67)
Approvals (5680)
Artificial intelligence (83)
Bankruptcy (99)
Best Places to Work (4544)
Biotechnology (233)
Breast cancer (121)
Cancer (1016)
Cardiovascular disease (83)
Career advice (132)
CAR-T (83)
Cell therapy (242)
Clinical research (40371)
Collaboration (385)
Compensation (155)
COVID-19 (1015)
C-suite (100)
Cystic fibrosis (72)
Data (1058)
Diabetes (95)
Diagnostics (1217)
Earnings (29059)
Events (47400)
Executive appointments (310)
FDA (6122)
Funding (364)
Gene editing (70)
Gene therapy (181)
GLP-1 (329)
Government (1066)
Healthcare (6559)
Infectious disease (1056)
Inflammatory bowel disease (100)
IPO (7222)
Job creations (859)
Job search strategy (127)
Layoffs (192)
Legal (1378)
Lung cancer (150)
Manufacturing (93)
Medical device (2564)
Medtech (2565)
Mergers & acquisitions (6173)
Metabolic disorders (288)
Neuroscience (1066)
NextGen: Class of 2025 (2013)
Non-profit (850)
Northern California (1211)
Obesity (156)
Opinion (93)
Parkinson's disease (82)
Patents (68)
People (25244)
Phase I (14249)
Phase II (18771)
Phase III (11875)
Pipeline (449)
Postmarket research (852)
Preclinical (5979)
Radiopharmaceuticals (207)
Rare diseases (226)
Real estate (1413)
Regulatory (8359)
Research institute (932)
Series A (71)
Southern California (1090)
Startups (1967)
United States (9601)
Vaccines (175)
Weight loss (92)
Date
Today (84)
Last 7 days (269)
Last 30 days (1249)
Last 365 days (20410)
2025 (1201)
2024 (20553)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14350)
2014 (10396)
2013 (7491)
2012 (7535)
2011 (7620)
2010 (7434)
Location
Africa (146)
Asia (17023)
Australia (2875)
California (2759)
Canada (875)
China (252)
Colorado (104)
Connecticut (116)
Delaware (64)
Europe (36611)
Florida (311)
Georgia (80)
Illinois (174)
Indiana (67)
Maryland (364)
Massachusetts (2189)
Minnesota (112)
New Jersey (683)
New York (760)
North Carolina (445)
Northern California (1211)
Ohio (88)
Pennsylvania (529)
South America (207)
Southern California (1090)
Texas (310)
Washington State (267)
263,055 Results for "hemoshear therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
HemoShear Attends Piper Sandler Conference
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, participated in the Piper Sandler Spring Biopharma Symposium being held in Boston, MA, Wednesday, May 17 through Thursday, May 18, 2023.
May 18, 2023
·
1 min read
BioCapital
HemoShear Therapeutics to Participate in Piper Sandler Healthcare Conference
HemoShear Therapeutics, Inc. will present at the 34th Annual Piper Sandler Healthcare Conference being held November 29 – December 1 in New York City.
November 17, 2022
·
1 min read
BioCapital
HemoShear Therapeutics to Participate in SVB Leerink Securities Biopharma Private Company Connect
HemoShear Therapeutics, Inc. today announced that it will participate in SVB Leerink Biopharma Private Company Connect being held virtually October 26-27.
October 18, 2022
·
1 min read
Business
HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer
HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare diseases, today announced the appointment of Brian Wamhoff , PhD, as interim chief executive officer.
August 25, 2022
·
4 min read
Business
HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics’ Gout Discovery Pipeline
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP).
September 21, 2022
·
3 min read
Business
HemoShear Develops New Human Tissue-Based Model of Rare Liver Disease Under Research Collaboration with Takeda
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has received a milestone payment under its October 2020 research collaboration and service agreement with Takeda.
August 10, 2022
·
2 min read
Business
HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer
HemoShear Therapeutics, Inc. has appointed Patrick Horn , MD, PhD, as Chief Medical Officer, effective January 1, 2022.
December 14, 2021
·
2 min read
Business
HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline
HemoShear Therapeutics, Inc. has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics plc
September 21, 2021
·
2 min read
Business
HemoShear Therapeutics Identifies Second Novel Target to Treat NASH Through Successful Collaboration with Takeda
HemoShear Therapeutics, Inc. announced today that a second target identified utilizing the company’s REVEAL-Tx ™ human disease modeling platform has been selected by Takeda Pharmaceutical Company Limited
November 16, 2021
·
4 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
1 of 26,306
Next
